Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-002915-23
    Sponsor's Protocol Code Number:ARGX-113-1904
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-09-30
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-002915-23
    A.3Full title of the trial
    A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
    Ensayo aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de efgartigimod PH20 SC en pacientes adultos con pénfigo (vulgar o foliáceo) (ADDRESS)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to assess the safety and efficacy of a subcutaneous formulation of efgartigimod PH20 SC in adults with Pemphigus (Vulgaris or Foliaceus)
    Un estudio para evaluar la seguridad y la eficacia de una formulación subcutanea de efgartigimod PH20 SC en adultos con pénfigo (Vulgar o Foliáceo)
    A.3.2Name or abbreviated title of the trial where available
    ADDRESS
    A.4.1Sponsor's protocol code numberARGX-113-1904
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of Sponsorargenx BV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportargenx BV
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationargenx BV
    B.5.2Functional name of contact pointRegulatory
    B.5.3 Address:
    B.5.3.1Street AddressIndustriepark Zwijnaarde 7
    B.5.3.2Town/ cityZwijnaarde
    B.5.3.3Post codeB-9052
    B.5.3.4CountryBelgium
    B.5.4Telephone number0034900834223
    B.5.6E-mailRegistroEspanolDeEstudiosClinicos@druginfo.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEfgartigimod PH20 SC
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEFGARTIGIMOD ALFA
    D.3.9.1CAS number 1821402-21-4
    D.3.9.2Current sponsor codeARGX-113
    D.3.9.4EV Substance CodeSUB180001
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number165
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pemphigus Vulgaris or Pemphigus Foliaceus
    Pénfigo vulgar o pénfigo foliáceo
    E.1.1.1Medical condition in easily understood language
    Blistering autoimmune diseases that affect the skin and mucous membranes
    Enfermedades autoinmunes ampollosas que afectan la piel y las membranas mucosas
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10052802
    E.1.2Term Pemphigus vulgaris
    E.1.2System Organ Class 100000004858
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10057069
    E.1.2Term Pemphigus foliaceus
    E.1.2System Organ Class 100000004858
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the efficacy of efgartigimod PH20 SC compared to placebo in the treatment of patients with Pemphigus vulgaris
    Demostrar la eficacia de efgartigimod PH20 SC en comparación con placebo en el tratamiento de pacientes con PV
    E.2.2Secondary objectives of the trial
    • To demonstrate the efficacy of efgartigimod PH20 SC in the treatment of patients with pemphigus vulgaris or pemphigus foliaceus
    • To assess the safety of efgartigimod PH20 SC in patients with PV or PF
    • To evaluate the effects of efgartigimod PH20 SC on quality of life (QoL) in patients with PV or PF
    • To evaluate the PK of efgartigimod PH20 SC in patients with PV or PF
    • To evaluate the PD of efgartigimod PH20 SC in patients with PV or PF
    • To evaluate the immunogenicity of efgartigimod PH20 SC in patients with PV or PF
    -Demostrar la eficacia de efgartigimod PH20 SC en el tratamiento de pacientes con PV o PF
    -Evaluar la seguridad de efgartigimod PH20 SC en pacientes con PV o PF
    -Evaluar los efectos de efgartigimod PH20 SC en la calidad de vida (CdV) de pacientes con PV o PF
    -Evaluar la farmacocinética (FC) de efgartigimod PH20 SC en pacientes con PV o PF
    -Evaluar la farmacodinamia (FD) de efgartigimod PH20 SC en pacientes con PV o PF
    -Evaluar la inmunogenicidad de efgartigimod PH20 SC en pacientes con PV o PF
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Evaluation of biomarkers of pemphigus pathology from skin biopsis
    Evaluación de biomarcadores de patología del pénfigo a partir de biopsia cutánea
    E.3Principal inclusion criteria
    1. Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits).
    2. The patient is male or female, and aged 18 years to 80 years at the time of signing the informed consent form (ICF).
    3. The patient has a clinical diagnosis of PV (mucosal, cutaneous, mucocutaneous) or PF which has been confirmed by cutaneous histology, positive direct immunofluorescence (IF), and positive indirect IF and/or ELISA.
    4. The patient meets 1 of the following profiles:
    a. Newly diagnosed disease with PDAI ≥15 at baseline and naïve to treatment.
    b. Newly diagnosed disease with PDAI ≥15 while receiving a first course of oral prednisone (or equivalent). According to clinical judgment, the patient has shown no significant improvement of PV or PF signs for at least 2 weeks before baseline and is considered fit to start prednisone
    treatment at 0.5 mg/kg qd at baseline.
    c. Experiencing flare with PDAI ≥15, a maximum of 4 years since diagnosis, and off prednisone therapy ± a conventional immunosuppressant (eg, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil). Note: conventional immunosuppressants must be discontinued before baseline.
    d. Experiencing flare with PDAI ≥15, a maximum of 4 years since diagnosis, and receiving a tapered dose of oral prednisone (or equivalent), provided that prednisone has been given at stable dose ± a conventional immunosuppressant (eg, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil) for at least 2 weeks and patients are fit to start prednisone treatment at 0.5 mg/kg qd at baseline. Note: conventional
    immunosuppressants must be discontinued before baseline.
    5. Women of childbearing potential:
    a. Must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline before trial medication can be
    administered.
    b. Must be on a stable regimen for at least 1 month of at least 1 highly effective method of contraception (ie, failure rate of less than 1% per year) during the trial and for 90 days after the last administration of IMP.
    6. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use effective contraception from first administration of IMP through 90 days after the last administration of the IMP. Male patients practicing true sexual abstinence (as consistent with preferred and usual life style) can be included. Sterilized male patients who have had a vasectomy and with documented absence of sperm post-procedure can be included. Male patients are not allowed to donate sperm from first administration of IMP through 90 days after the last dose of IMP.
    1.Capacidad para comprender los requisitos del ensayo, otorgar el consentimiento informado por escrito (incluido el consentimiento para el uso y la divulgación de información médica relacionada con la investigación), disposición y capacidad para cumplir los procedimientos del protocolo del ensayo (incluidas las visitas del ensayo exigidas)
    2.El paciente es un varón o una mujer de 18 a 80 años de edad en el momento de firmar el documento de consentimiento informado (DCI)
    3.El paciente tiene un diagnóstico clínico de PV (mucoso, cutáneo, mucocutáneo) o FP que se ha confirmado mediante histología cutánea, inmunofluorescencia directa (IF) positiva e IF indirecta positiva o ELISA
    4.El paciente cumple uno de los siguientes perfiles:
    a. Enfermedad recién diagnosticada con una puntuación de la actividad PDAI ≥ 15 en el momento basal y sin tratamiento previo
    b. Enfermedad recién diagnosticada con una puntuación de la actividad PDAI ≥ 15 durante un primer ciclo de prednisona oral (o equivalente). Según el criterio clínico, el paciente no ha experimentado una mejoría significativa de los signos de PV o PF durante al menos 2 semanas antes del momento basal y se considera apto para iniciar el tratamiento con prednisona en una dosis de 0,5 mg/kg una vez al día en el momento basal.
    c. Presencia de brote con una puntuación de la actividad PDAI ≥ 15, un máximo de 4 años desde el diagnóstico y sin tratamiento con prednisona ± un inmunodepresor convencional (por ejemplo, azatioprina, ciclofosfamida, metotrexato, micofenolato mofetilo). Nota: Los inmunodepresores convencionales deberán suspenderse antes del momento basal.
    d. Presencia de brote con una puntuación de la actividad PDAI ≥ 15, un máximo de 4 años desde el diagnóstico y en tratamiento con una dosis reducida de prednisona oral (o equivalente), siempre que prednisona se haya administrado en una dosis estable ± un inmunodepresor convencional (p. ej., a zatioprina, ciclofosfamida, metotrexato, micofenolato mofetilo) durante al menos 2 semanas y los pacientes sean aptos para iniciar el tratamiento con prednisona en una dosis de 0,5 mg/kg una vez al día en el momento basal. Nota: Los inmunodepresores convencionales deberán suspenderse antes del
    momento basal.
    5.Mujeres en edad fértil:
    a. Deben tener una prueba de embarazo en suero negativa en la selección y una prueba de embarazo en orina negativa en el momento basal antes de poder administrar la medicación del ensayo
    b. Deben estar recibiendo una pauta estable durante 1 mes como mínimo de al menos un método anticonceptivo muy eficaz (es decir, tasa de fallos inferior al 1% anual) durante el ensayo y durante 90 días después de la última administración del MEI.
    6.Los varones no esterilizados que mantengan relaciones sexuales con una pareja femenina en edad fértil deberán usar un método anticonceptivo eficaz desde la primera administración del MEI hasta 90 días después de la última dosis. Podrán participar varones que practiquen una abstinencia sexual real (cuando esté en consonancia con el modo de vida preferido y habitual). Podrán participar
    también varones esterilizados que se hayan sometido a una vasectomía con aspermia documentada después del procedimiento. Los varones no podrán donar semen desde la primera administración del MEI hasta 90 días después de la última dosis del MEI.
    E.4Principal exclusion criteria
    1. Patient has a confirmed diagnosis of paraneoplastic pemphigus, drug-induced pemphigus, pemphigus vegetans, pemphigus erythematosus, or any other non-PV/non-PF autoimmune blistering disease.
    2. Patients with mild disease severity as defined by PDAI <15 at baseline.
    3. Patients who show a significant improvement of PV or PF in the period from screening to baseline according to clinical judgment (eg, the patient has achieved DC or a substantial reduction in PDAI activity score during screening period).
    4. The patient has been administered therapy other than oral prednisone or conventional immunosuppressants (eg, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil) within 2 months before the baseline visit and that can affect clinical disease activity.
    5. Use of any monoclonal antibody (including rituximab or another anti-CD20 biologic) within 6 months before the baseline visit.
    6. Known hypersensitivity to any of the components of the administered treatments.
    7. The patient has a known contraindication to oral prednisone.
    8. The patient has a history of refractory disease, as defined by a failure to respond to first-line and second-line therapies.
    9. Patients who have a history of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before first IMP administration. Patients with any of the following cancers can be included at any time:
    a. Adequately treated basal cell or squamous cell skin cancer
    b. Carcinoma in situ of the cervix
    c. Carcinoma in situ of the breast
    d. Incidental histological finding of prostate cancer (TNM stage T1a or T1b)
    10. Patients with clinical evidence of other significant serious disease or patients who recently underwent or have planned a major surgery during the period of the trial, or any other condition in the opinion of the investigator, that could confound the results of the trial or put the patient at undue risk.
    11. Pregnant and lactating women and those intending to become pregnant during the trial or within 90 days after the last administration of IMP.
    12. Current or history (ie, within 12 months of screening) of alcohol, drug, or medication abuse.
    13. Any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of PV or PF or put the participant at undue risk.
    14. The patient has a Karnofsky performance score <60%.
    15. Vaccination with live/attenuated viral vaccines within 28 days prior to randomization.
    16. The patient has clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection.
    17. Positive serum test at screening for an active viral infection with any of the following conditions:
    a. Hepatitis B Virus (HBV)
    b. Hepatitis C Virus (HCV)
    c. Human immunodeficiency virus (HIV)
    18. The patient has total immunoglobulin G (IgG) <6 g/L at screening.
    19. The patient has previously participated in a trial with efgartigimod and has received at least 1 administration of IMP.
    20. Use of an investigational drug within 3 months or 5 half-lives of the drug (whichever is longer) prior to first IMP administration.
    1. paciente tiene un diagnóstico confirmado de pénfigo paraneoplásico, pénfigo inducido por fármacos, pénfigo vegetante, pénfigo eritematoso o cualquier otra enfermedad ampollosa autoinmunitaria no PV/no PF.
    2.Pacientes con enfermedad de intensidad leve definida por una puntuación de la actividad PDAI < 15 en el momento basal.
    3.Pacientes que muestren una mejoría significativa del PV o el PF en el periodo comprendido entre la selección y el momento basal según el criterio clínico (p. ej., el paciente ha logrado el CE o una reducción considerable de la puntuación de la actividad PDAI durante el periodo de selección).
    4. paciente ha recibido tratamientos distintos de prednisona oral o inmunodepresores
    convencionales (p. ej., azatioprina, ciclofosfamida, metotrexato, micofenolato mofetilo) en los 2 meses previos a la visita basal que pueden afectar a la actividad clínica de la enfermedad.
    5.Uso de cualquier anticuerpo monoclonal (incluido rituximab u otro fármaco biológico anti-CD20) en los 6 meses previos a la visita basal.
    6.Hipersensibilidad conocida a cualquiera de los componentes de los tratamientos administrados
    7.El paciente tiene una contraindicación conocida a prednisona oral
    8.El paciente tiene antecedentes de enfermedad resistente, definida por falta de respuesta a lostratamientos de primera y segunda línea
    9.Pacientes con antecedentes de neoplasias malignas, a menos que se consideren curadas con un
    tratamiento adecuado sin signos de recidiva durante ≥ 3 años antes de la primera administración del MEI. Se puede incluir en cualquier momento a pacientes con cualquiera de los cánceres siguientes:
    a. Carcinoma de piel basocelular o espinocelular tratados correctamente
    b. Carcinoma in situ de cuello uterino
    c. Carcinoma in situ de mama
    d. Hallazgo histológico fortuito de cáncer de próstata (estadio TNM T1a o T1b)
    10.Pacientes con signos clínicos de otra enfermedad grave importante o pacientes que se hayan sometido recientemente o tengan previsto someterse a una intervención de cirugía mayor durante el período del ensayo, o cualquier otro proceso que, en opinión del investigador, pueda confundir los resultados del ensayo o suponer un riesgo excesivo para el paciente
    11.Mujeres embarazadas y lactantes y mujeres que pretendan quedarse embarazadas durante el ensayo o en los 90 días siguientes a la última administración del MEI
    12.Presencia o antecedentes (en los 12 meses previos a la selección) de abuso de alcohol, drogas omedicamentos
    13.Cualquier otra enfermedad autoinmunitaria conocida que, en opinión del investigador, pueda interferir en una evaluación exacta de los síntomas clínicos del PV o PF o suponer un riesgo excesivo para el participante.
    14.El paciente tiene una puntuación funcional de Karnofsky < 60%
    15.Vacunación con vacunas de virus vivos/atenuados en los 28 días previos a la aleatorización
    16.El paciente presenta una infección bacteriana, viral o fúngica activa o crónica, clínicamente significativa y no controlada.
    17.Análisis sérico positivo en la selección de una infección viral activa con cualquiera de las situaciones siguientes:
    a. Virus de la hepatitis B (VHB)
    b. Virus de la hepatitis C (VHC)
    c. Virus de la inmunodeficiencia humana (VIH)
    18.El paciente tiene una inmunoglobulina G (IgG) total < 6 g/l en la selección
    19.El paciente ha participado anteriormente en un ensayo de efgartigimod y ha recibido al menos 1 administración del MEI.
    20.Uso de un fármaco en investigación en los 3 meses o 5 semividas del medicamento (lo que suponga más tiempo) previos a la primera administración del MEI.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of Pemphigus vulgaris patients who achieve complete clinical remission (CR) on minimal prednisone therapy within 30 weeks
    Proporción de pacientes con PV que obtengan una remisión clínica completa (RC) con
    tratamiento mínimo con prednisona en 30 semanas.
    E.5.1.1Timepoint(s) of evaluation of this end point
    week 30
    semana 30
    E.5.2Secondary end point(s)
    1. Proportion of PV and PF patients who achieve complete clinical CR on minimal prednisone therapy within 30 weeks
    2. Time to Disease Control (DC) in PV patients
    3. Time to CR in PV patients
    4. Cumulative prednisone dose over the trial in PV patients
    5. Time to DC in PV and PF patients
    6. Time to complete CR in PV and PF patients
    7. Cumulative prednisone dose over the trial in PV and PF patientss
    8. Rate of treatment failure
    9. Rate of flare
    10. PDAI at each visit
    11. Incidence and severity of TEAEs, AESIs, and SAEs by System Organ Class (SOC) and Preferred Term (PT).
    12. EuroQol Five-Dimension Five-Level Scale (EQ-5D-5L) score - 30 weeks treatment period
    13. Autoimmune Bullous Quality of Life (ABQOL) score
    14. Efgartigimod serum concentrations
    15. Total IgG and subtype (IgG1, IgG2, IgG3, IgG4) serum levels
    16. Anti Dsg-1 and -3 autoantibodies serum levels
    17. Anti-drug antibodies (ADA) to efgartigimod PH20 SC
    1-Proporción de pacientes con PV y FP que logran una RC clínica completa con una terapia mínima con prednisona en 30 semanas
    2.Tiempo hasta el CE en los pacientes con PV
    3-Tiempo hasta la RC en los pacientes con PV
    4-Dosis acumulada de prednisona durante el ensayo en los pacientes con PV
    5-Tiempo hasta el CE en los pacientes con PV y PF
    6-Tiempo hasta la RC en los pacientes con PV y PF
    7-Dosis acumulada de prednisona durante el ensayo en los pacientes con PV y PF
    8-Tasa de fracasos del tratamiento
    9-Tasa de brotes
    10-PDAI en cada visita
    11-Incidencia e intensidad de los acontecimientos adversos surgidos durante el tratamiento (AAST), los acontecimientos adversos de interés especial (AAIE) y los acontecimientos adversos graves (AAG) por clase de órgano y sistema (SOC) y término preferente (TP)
    12-Puntuación de EuroQol de 5 dimensiones y 5 niveles (EQ-5D-5L) -Periodo de tratamiento de 30 semanas
    13-Puntuación de ABQOL (Calidad de vida en la enfermedad autoinmunitaria ampollosa)
    14-Concentración sérica de efgartigimod
    15-Concentraciones séricas de IgG total y subtipo (IgG1, IgG2, IgG3, IgG4)
    16-Concentraciones séricas de autoanticuerpos anti-Dsg-1 y anti-Dsg-3
    17-Anticuerpos (ACF) contra efgartigimod rHyPH20 SC
    E.5.2.1Timepoint(s) of evaluation of this end point
    endpoint 1: 30 weeks treatment period
    endpoints 2 to 9; up to 30 weeks
    endpoint 10 & 11: up to 41 weeks
    endpoint 12 & 13: 30 weeks treatment period
    endpoint 14: up to 38 weeks
    endpoint 15 & 16: up to 41 weeks
    endpoint 17: Up to 38 weeks
    criterio de valoración 1: período de tratamiento de 30 semanas
    criterio de valoración 2 a 9: hasta 30 semanas
    criterio de valoración 10&11: hasta 41 semanas
    criterio de valoración 12&13: período de tratamiento de 30 semanas
    criterio de valoración 14: hasta 38 semanas
    criterio de valoración 15&16: hasta 41 semanas
    criterio de valoración 17: hasta 38 semanas
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    Inmunogenicidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA51
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Bulgaria
    France
    Georgia
    Germany
    Greece
    Hungary
    India
    Israel
    Italy
    Japan
    Poland
    Romania
    Russian Federation
    Spain
    Turkey
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    For the complete study, the end of the study is defined as last participant last visit in trial ARGX 113-1904
    Para el estudio completo, el final del estudio se define como la última visita del último participante en el ensayo ARGX 113-1904
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days28
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days28
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 105
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 45
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Under certain conditions described in the protocol, the patients may be eligible to roll over to the open-label extension trial ARGX-113-1905. For patients, randomized to the efgartigimod PH20 SC or placebo treatment arm in ARGX-113-1904, trial ARGX-113-1905 provides extended or first treatment and re-treatment options in the respective treatment arms. argenx is currently assessing the appropriateness and possibility of making efgartigimod PH20 SC available for trial participants post-trial.
    Según condiciones descritas en protocolo,los pacientes pueden ser elegibles para pasar al ensayo de extensión abiertoARGX-113-1905.Para pacientes randomizados al brazo de tratam con efgartigimod PH20SC o placebo en ARGX-113-1904,ARGX-113-1905 proporciona opciones de tratam prolongado o de 1er tratam y retratam en los respectivos brazos.argenx está evaluando actualmente conveniencia y posibilidad de hacer que efgartigimod PH20SC esté disponible para los participantes del ensayo después del ensayo
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-12-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-12-03
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-08-22
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 22:11:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA